Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast ...

Upon identification of a positive (HER2) Dual In Situ Hybridization (DISH ... sparing terminal duct-lobular structures, and involving a fibroadenoma. Notably, the carcinoma displayed mucinous features ...

HER2-positive cancers, such as certain types of breast cancer, are aggressive and often have limited treatment options. RAD202 represents a novel approach targeting the HER2 receptor using ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more. See Healio’s ...

In patients with HR-positive/HER2-positive breast cancer, the 5-year breast cancer-specific survival rate was 99.0% for patients who received adjuvant chemotherapy ...

unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. Zanidatamab is a bispecific HER2-directed antibody that induces complement ...

Cohort 1 included 80 patients with HER2-positive disease, defined as IHC2+/3+ status. Cohort 2 included seven patients with IHC0/1+ status. Objective response rate per independent central review ...

Traditionally, the assessment of HER2 status in BC has been binary, categorizing tumors as either negative or positive. However ... resulting in superior discrimination between TNBC and fibroadenoma ...